Aptamer Sciences Inc Logo

Aptamer Sciences Inc

Clinical-stage company developing aptamer-based therapeutics for oncology.

291650 | KO

Overview

Corporate Details

ISIN(s):
KR7291650000
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로228번길 15 3동 301호(삼평동, 판교세븐벤처밸리1), 성남시

Description

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
주식등의대량보유상황보고서(일반)
Korean 84.4 KB
2025-09-15 00:00
주식등의대량보유상황보고서(일반)
Korean 104.9 KB
2025-09-09 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-09-09 00:00
주요사항보고서(유상증자결정)
Korean 39.4 KB
2025-09-09 00:00
주요사항보고서(전환사채권발행결정)
Korean 40.2 KB
2025-09-09 00:00
주요사항보고서(유상증자결정)
Korean 51.0 KB
2025-09-09 00:00
주주총회소집결의 (임시주주총회)
Korean 5.9 KB
2025-09-09 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 77.9 KB
2025-09-08 00:00
경영권변경등에관한계약체결
Korean 15.1 KB
2025-08-20 00:00
단일판매ㆍ공급계약체결
Korean 10.3 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 891.5 KB
2025-07-03 00:00
풍문또는보도에대한해명
Korean 4.4 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 745.9 KB
2025-04-07 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.2 KB
2025-03-27 00:00
정기주주총회결과
Korean 26.5 KB

Automate Your Workflow. Get a real-time feed of all Aptamer Sciences Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptamer Sciences Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptamer Sciences Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.